Data-driven analysis backed by 1,600++ verified biopharma transactions. Licensing benchmarks, negotiation strategies, and market intelligence.
Mega-deal activity exploded from zero to 61 transactions in the first half of 2026 — a 6100% increase period over period. Eli Lilly, GSK, and Ipsen are leading a land grab that's reshaping deal structures and leverage dynamics across biopharma BD.
Other deal activity jumped 3600% in the first half of 2026, leaping from zero recorded deals to 36 in six months. Mega-transactions like Merck KGaA's $11.3B Bio-Techne acquisition and Pfizer's $2B YaoPharma licensing deal are rewriting the playbook for cross-category dealmaking.
Mega-deal activity exploded from zero to 61 transactions between February and August 2026 — a 6100% surge that rewrites the competitive playbook for BD teams. Here's what's behind it and what it means for your next negotiation.
AbCellera and Vertex have formed a partnership to develop next-generation T-cell engagers, signaling sustained Big Pharma appetite for differentiated oncology platforms. We break down what the deal structure likely looks like against current biopharma deal benchmarks 2026 and what it means for BD teams evaluating similar assets.
Johnson & Johnson has secured an option to acquire in vivo CAR-T developer Sail Bio for nearly $2.6B — blowing past Phase 2 immunology total deal value benchmarks by a significant margin. The structure signals how seriously Big Pharma is pricing next-generation cell therapy delivery, and what BD teams need to know before their next CAR-T negotiation.
Mega-deal activity exploded from zero to 61 transactions in the first half of 2026 — a 6100% increase. Eli Lilly, GSK, and Ipsen are leading the charge. Here's what's driving the surge and what it means for BD teams right now.
Deal activity classified as "other" — including platform technology acquisitions, tools licensing, and cross-sector partnerships — surged 3900% in the first half of 2026. Merck KGaA's $11.3B Bio-Techne deal and Pfizer's $2B YaoPharma partnership signal a structural shift in how pharma is sourcing innovation.
Mega-deal activity surged 6100% in the first half of 2026 — from zero transactions to 61 in six months. Eli Lilly alone accounted for nearly $5B in total deal value across two mega-deals licensing 2026 transactions in a single week.
Deals classified outside traditional therapeutic categories surged 3900% in the first half of 2026, jumping from zero to 39 transactions. The Merck KGaA–Bio-Techne mega-deal and Pfizer's YaoPharma partnership signal a structural shift in how pharma is sourcing value.
Mega-deal activity exploded from zero to 61 transactions in six months — a 6100% increase that rewrites the biopharma licensing landscape. Eli Lilly alone accounted for $4.7B in total deal value across two transactions in a single week. Here's what's driving it, who's winning, and what BD teams should do right now.
Mega-deal activity surged 6100% in the first half of 2026, with 61 transactions recorded after a complete shutout in the prior six months. Eli Lilly alone accounted for two deals exceeding $2B in total deal value within a single week. Here's what's behind the shift and what it means for your next negotiation.
Other deal activity exploded from zero to 39 transactions in the first half of 2026 — a 3900% increase. The Merck KGaA–Bio-Techne mega-deal and Pfizer's YaoPharma licensing agreement are reshaping how BD teams think about platform acquisitions and cross-border deals outside traditional therapeutic silos.
Mega-deal activity jumped from zero to 61 transactions in six months — a 6100% increase that signals a fundamental shift in how Big Pharma is filling pipeline gaps. Here's what's driving it and what it means for your next negotiation.
Small molecule licensing activity exploded 3067% in the first half of 2026, jumping from 3 deals to 95. Big Pharma patent cliffs, Chinese biotech exports, and a renewed appetite for oral therapeutics are converging into the most aggressive small molecule deal environment in a decade.
Rare disease deal activity exploded from 1 transaction to 34 in six months — a 3300% increase. Five deals alone represent over $11B in total deal value, signaling a structural shift in how pharma is filling pipeline gaps in orphan indications.
Deal activity in the 'other' category — platform technology, tools, and non-traditional licensing — exploded by 3900% in the first half of 2026. Bio-Techne's $11.3B tie-up with Merck KGaA and Novartis's move on Generate:Biomedicines signal that pharma's appetite has shifted beyond molecules to the infrastructure that creates them.
Sixty-one mega-deals closed between January and July 2026 after a complete shutout in the prior six months — a 6100% spike that rewrites the competitive landscape. Here's what's driving it, who's buying, and what BD teams should do right now.
39 deals closed in the first half of 2026 in categories that defy traditional therapeutic area classification — up from zero in the prior six months. The Bio-Techne/Merck KGaA $11.3B acquisition and Pfizer's $2B+ YaoPharma partnership are reshaping how BD teams think about platform-level dealmaking.
Mega-deal activity exploded from zero to 61 transactions in six months — a 6100% increase that signals a fundamental shift in how Big Pharma is filling pipeline gaps. Here's the data, the drivers, and what BD teams should do about it right now.
Peptide licensing activity exploded 1200% period-over-period in the first half of 2026, jumping from 1 deal to 13. Biogen's $5.6B Apellis acquisition and Lilly's Hanmi tie-up define the new competitive dynamics. Here's what it means for your next negotiation.
Hematology deal activity exploded from zero to 16 transactions in the first half of 2026 — a 1600% surge driven by Big Pharma pipeline anxiety and a $2B mega-deal from Incyte. Here's what the data says and what it means for your next negotiation.
Vaccine deal activity exploded from zero transactions to 17 in six months — a 1700% surge that signals a fundamental repricing of vaccine assets. Eli Lilly alone anchored multiple deals exceeding $2B in total deal value. Here's what's driving it and what it means for your next negotiation.
Deal activity in the 'other' modality category surged 1860% in six months — from 5 deals to 98. Mega-deals from Novo Nordisk, AstraZeneca, and Novartis reveal a strategic land-grab in non-traditional modalities that BD teams can no longer afford to treat as edge cases.
ADC licensing activity exploded by 1900% in the first half of 2026, jumping from 1 deal to 20 in six months. GSK, Novartis, and Whitehawk are leading the charge. Here's what's driving it and what BD teams need to do right now.
Twenty bispecific antibody deals closed between January and July 2026 — up from zero in the prior six months. Pfizer alone committed $2.5B in upfront payments across two 3SBio transactions. Here's what's driving the surge and what it means for your next negotiation.
Small molecule deal activity exploded 3067% in the first half of 2026, jumping from 3 deals to 95. The surge is reshaping small molecule licensing 2026 dynamics — here's what's driving it and what BD teams need to do now.
Rare disease licensing went from 1 deal to 34 in six months — a 3300% increase that's reshaping BD strategy across pharma. We analyze the drivers, the marquee transactions, and the tactical implications for buyers and sellers.
Forty deals in six months versus zero in the prior half — other deal trends 2026 represent the most dramatic category shift we've tracked. Merck KGaA's $11.3B Bio-Techne acquisition and Pfizer's $2B YaoPharma licensing deal reveal why pharma is hunting outside traditional therapeutic silos.
Mega-deal activity surged 6100% in the first half of 2026 — from zero transactions to 61 in six months. Eli Lilly alone accounted for nearly $5B in total deal value across two deals in a single week. Here's what's driving it and what BD teams should do now.
Janssen has executed 9 deals since 2011 with a 14.6% average upfront ratio — among the most buyer-friendly profiles in large pharma. Their deal activity reveals a company anchored in hematology and co-development structures, with recent moves suggesting a platform expansion beyond Imbruvica.
Gilead has executed 10 deals since mid-2017, committing over $45 billion in total deal value with a heavy oncology tilt and an average upfront ratio of 43.8%. Here's what the data says about their strategic thesis — and what it means if you're pitching them.
AstraZeneca's $4.7B option deal with CSPC for next-generation cardiometabolic small molecules is the largest China-originated cardio-licensing transaction announced this year. Here's what the CSPC AstraZeneca deal structure tells us about conviction, risk allocation, and where the cardiometabolic market is heading.
Mega-deal activity exploded from zero to 61 transactions in the first half of 2026 — a 6100% increase. Eli Lilly alone accounted for multiple billion-dollar-plus licensing plays in a single week. Here's what the data says and what it means for your next negotiation.
BMS has executed 13 deals since mid-2019, committing over $48 billion in total deal value across oncology, immunology, and cardiovascular. Their 2025–2026 acceleration — anchored by a $15.2B collaboration and a $5B Phase 2 acquisition — signals a company rebuilding its pipeline through external innovation at scale.
Boehringer Ingelheim has executed 15 deals since February 2020, with a striking concentration in neurology and immunology option structures averaging just 14.9% upfront-to-TDV. Here's what their deal activity reveals about pipeline strategy and what it means if you're pitching them.
Bristol Myers Squibb executed 15 deals between 2022 and mid-2026, with a single mega-collaboration with Hengrui anchoring a $15.2B total deal value. Oncology dominates the portfolio, but the deal structures reveal a company aggressively externalizing early-stage risk while locking in optionality across 13+ programs at once.
Takeda has executed 16 deals since January 2019, with a sharp pivot toward oncology and hematology in 2025–2026. Their 34.3% average upfront ratio and preference for option-based structures reveal a buyer playing offense — but on disciplined terms.
Eli Lilly just dropped $2.3B to acquire LimmaTech Biologics and its vaccine platform — its largest pure-play vaccine bet to date. Here's what the deal structure tells us about Lilly's strategic pivot and what it means for vaccine asset valuations across the board.
Johnson & Johnson executed 16 deals between 2017 and mid-2026, with a sharp acceleration into oncology platforms and late-stage acquisitions. Their 50.5% average upfront ratio signals aggressive conviction bets — not exploratory option plays. Here's what the data says about where J&J is headed and how to position your asset accordingly.
Pfizer committed $1.3B upfront — the largest publicly disclosed option payment for a bispecific immuno-oncology asset this year — to lock in 3SBio's bispecific portfolio. The $6.3B total deal value signals Pfizer's aggressive bet that bispecifics will define next-generation I-O, and it resets the valuation floor for every comparable asset in development.
N/A (standalone) executed 17 deals between mid-2022 and early 2024, spanning 10 therapeutic areas with total deal values ranging from $300M to $8.2B. Dermatology and infectious disease dominate the portfolio, but the breadth tells a more interesting story about opportunistic platform-building.
Gilead Sciences has executed 20 deals since 2019, committing over $18B in total deal value across oncology, immunology, and infectious disease. Their 2026 deal activity reveals a dramatic escalation in deal size and a clear pivot toward platform acquisitions and late-stage oncology bets.
Biogen has executed 21 deals since mid-2018, culminating in a $6B acquisition of Apellis that fundamentally reshapes its therapeutic identity. Here's what the data reveals about Biogen's evolving deal thesis — and what it means if you're pitching them.
RayzeBio/BMS paid $350M upfront to Philochem for a Phase 1 radiopharmaceutical program in a deal valued at $1.4B. The 25% upfront-to-TDV ratio signals aggressive conviction in targeted radiopharmaceuticals — and resets valuation benchmarks for every Phase 1 radiopharm asset on the market.
Novo Nordisk executed 21 deals between 2018 and mid-2026, committing billions to metabolic and adjacent therapeutic areas. Their 39.6% average upfront ratio and heavy tilt toward GLP-1 pipeline expansion reveal a company playing offense — not just defending its obesity franchise.
Across 13 preclinical small molecule metabolic deals, the median upfront payment is $115M with a P25–P75 range of $75M–$285M. The spread is massive — and the drivers are identifiable. Here's how to benchmark your asset.
The median upfront for an approved small molecule women's health deal is $875M across 19 transactions, but the P25–P75 spread runs from $174M to $1.8B. Here's what drives that 10x range — and where your asset likely lands.
The median upfront for an approved rare disease deal sits at $3,050M across 17 comparable transactions, with a striking P25–P75 range of $450M to $11,600M. Here's what drives that 25x spread and where your asset likely falls.
The median upfront for an approved small molecule infectious disease deal is $139M, based on 8 completed transactions. The interquartile range spans $75M to $318M — a 4x spread driven by competitive positioning, portfolio urgency, and regulatory differentiation.
Sanofi has executed 35 deals since 2017, committing over $15B in total deal value in 2026 alone across immunology, oncology, and infectious disease. Their 42.8% average upfront ratio signals a buyer willing to pay for conviction — but only on their terms.
Pfizer has executed 41 deals since late 2020, with a dramatic tilt toward oncology mega-deals and option structures in 2025–2026. Their 34.8% average upfront ratio signals a buyer who demands milestone-heavy structures — but is willing to pay headline numbers north of $10B to lock up platforms.
The median upfront for a preclinical small molecule immunology deal is $190M across 16 analyzed transactions, with a P25–P75 range of $61M to $333M. Here's what drives the spread and how to position your asset.
The median upfront for a preclinical gene therapy ophthalmology deal is $40M across 7 benchmarked transactions, with a P25–P75 range of $20M–$50M. Here's what drives the spread and how to position your asset.
The median upfront for a preclinical gene therapy neurology deal is $73M across 28 transactions, but the interquartile range spans $39M to $165M. What separates the bottom quartile from the top — and where does your asset land?
The median upfront for an approved CDMO metabolic deal is $1,847M, but the interquartile range spans $604M to $6,300M — a 10x spread driven by asset differentiation, manufacturing infrastructure value, and buyer urgency. Here's how to benchmark your deal against the data.
AstraZeneca paid $600M upfront — a 40% upfront-to-TDV ratio — to license Dizal Pharmaceutical's approved EGFR inhibitor Zegfrovy in a deal totaling $1.5B. Here's what the Dizal Pharmaceutical AstraZeneca deal structure tells us about where approved oncology small molecules are being priced right now.
Novo Nordisk is paying $2.4B to acquire Omeros and its lead asset zaltenibart. The deal signals aggressive portfolio expansion beyond metabolic disease. Here's what the structure tells us about buyer conviction, strategic logic, and valuation benchmarks for comparable assets.
Oligonucleotide licensing 2026 exploded from 1 deal to 25 in six months — a 2400% increase. The Arrowhead–Sarepta $10B TDV megadeal anchors a wave that's reshaping deal structures and valuations across the modality.
Pfizer committed $1.2B upfront to license 3SBio / Shenyang Sunshine's PD-1/VEGF bispecific SSGJ-707, with a total deal value of $6.2B. The 19.4% upfront-to-TDV ratio signals high conviction paired with disciplined risk allocation. Here's what the deal structure tells us about bispecific valuations and Pfizer's oncology reboot.
The median upfront for an approved small molecule ophthalmology deal is $1,750M across 11 benchmarked transactions, with a P25–P75 range spanning $760M to $5,200M. This article breaks down what drives that spread and how to position your asset accordingly.
Jazz Pharmaceuticals committed up to $4.0B in total deal value for AbCellera's T cell engager program — one of the largest bispecific collaboration deals of 2026. Here's what the AbCellera Biologics Jazz Pharmaceuticals deal structure tells us about buyer conviction, risk allocation, and where TCE valuations are headed.
Other deal activity surged 4100% in the first half of 2026 — from 1 deal to 42 in six months. Mega-deals like Bio-Techne/Merck KGaA ($11.3B) and YaoPharma/Pfizer ($2.05B TDV) signal a fundamental reshuffling of how pharma is structuring non-traditional partnerships.
AstraZeneca's $18.5B collaboration with CSPC Pharmaceutical for an obesity/chronic disease program marks one of the largest licensing deals of 2026. The $1.2B upfront signals massive buyer conviction, but the deal structure reveals a calculated risk-sharing framework worth dissecting.
Mega-deal activity exploded 5000% in the first half of 2026, jumping from zero transactions to 50 in six months. AstraZeneca's $18.5B TDV deal with CSPC and Jazz's $4B pact with AbCellera headline a trend that is reshaping leverage dynamics across biopharma BD.
Eli Lilly executed 38 deals between February 2025 and July 2026, with a 48.9% average upfront ratio and heavy concentration in neurology and oncology. Here's the full breakdown — deal structures, therapeutic thesis, and tactical advice for biotechs pitching Lilly.
GSK closed 39 deals between mid-2021 and mid-2026, committing over $25B in total deal value to oncology, cardiovascular, and infectious disease assets. Here's what their deal activity reveals about their pipeline thesis — and what it means if you're pitching to them.
The median upfront for an approved small molecule hematology deal is $2000M, based on 7 completed transactions. But the interquartile range spans $1800M to $5100M — a $3.3B gap driven by competitive positioning, commercial traction, and buyer urgency.
Oligonucleotide licensing 2026 has exploded — 25 deals in H1 vs. 1 in the prior half. The Arrowhead-Sarepta mega-deal anchors a trend driven by delivery breakthroughs and Big Pharma pipeline panic. Here's the full breakdown and what BD teams should do about it.
Merck executed 40 deals between August 2019 and mid-2026, deploying billions across oncology, mega-deals, and emerging TAs. The 41.4% average upfront ratio and recent acquisition spree reveal a company in aggressive pipeline-building mode — here's what it means for biotechs and investors.
Antibody licensing activity exploded 2900% in the first half of 2026, jumping from 1 deal to 30 in six months. Pfizer's $10B Innovent pact and Roche's double-dip with Xencor anchor the surge. Here's what it means for BD teams pricing and structuring antibody deals right now.
AstraZeneca executed 42 deals between April 2020 and July 2026, with an average upfront ratio of 36.7% of total deal value. Their recent moves — including an $18.5B obesity mega-deal and a $5.3B AI-led chronic disease collaboration — signal a strategic pivot beyond oncology dominance.
Deal activity in the 'other' category exploded by 4500% in the first half of 2026, jumping from 1 transaction to 46 in six months. The signal is unmistakable: pharma is aggressively pursuing non-traditional deal structures and cross-platform partnerships that defy legacy therapeutic-area classification.
The median upfront for a preclinical mRNA infectious disease deal is $75M across 11 analyzed transactions, but the interquartile range spans $26M to $163M. Where your asset lands in that range depends on mechanism differentiation, buyer urgency, and competitive landscape density.
BioPharma Dive delivers strong editorial coverage. Ambrosia delivers 14 real-time benchmarking engines across 1,500+ deals. Here's which tool actually helps you negotiate a licensing deal.
Mega-deal activity exploded from 0 to 47 transactions between H2 2025 and H1 2026 — a 4700% surge. We break down the drivers, the marquee deals, and what BD teams should do about it right now.
Deal activity classified outside traditional therapeutic-area categories surged 4700% in the first half of 2026, from 1 deal to 48. Bio-Techne's $11.3B Merck KGaA deal and Nurix's $1.8B Gilead partnership signal a structural shift toward platform-level transactions that defy neat TA buckets.
The median upfront for an approved small molecule cardiovascular deal sits at $350M, but the P25–P75 range spans $185M to $13.1B. That 70x spread tells you everything about how asset differentiation, competitive dynamics, and buyer strategy reshape deal economics in this space.
The median upfront for a preclinical gene therapy cardiovascular deal is $98M, based on 10 comparable transactions. But the P25–P75 spread of $62M–$224M tells a more important story about what actually drives pricing at this stage.
The median upfront for a preclinical peptide dermatology deal is $525M, with a P25–P75 range of $163M to $950M across 4 benchmarked transactions. Here's what drives the 6x spread and where your asset likely falls.
The median upfront for a preclinical oligonucleotide gastroenterology deal sits at $35M, based on 5 comparable transactions from 2023–2025. But the range stretches to $60M at P75 — and one outlier hit $150M. Here's what drives the spread and how to position your asset.
The median upfront for an approved monoclonal antibody immunology deal sits at $8,700M across 7 benchmarked transactions. The interquartile range spans $4,650M to $24,250M — a $19.6B gap driven by competitive positioning, franchise value, and buyer urgency. Here's how to read the data and position your asset.
The median upfront for an approved small molecule neurology deal sits at $1,375M across 10 recent transactions — but the spread from $485M to nearly $6B at the quartiles tells a more important story. Here's exactly what drives that range and where your asset likely falls.
Roche committed $700M in total deal value to Nurix Therapeutics for a protein degrader collaboration announced July 9, 2026. The deal structure signals Roche's aggressive re-entry into targeted protein degradation — and resets valuation expectations for the entire modality.
Royalty Pharma committed $2.0B in total deal value to secure a royalty interest in Revolution Medicines' daraxonrasib — a Phase 3 small molecule. Here's what the Revolution Medicines Royalty Pharma deal structure tells us about current mega-deal pricing and what it means for comparable assets in your pipeline.
Pharma BD teams need deal benchmarking tools that go beyond headline numbers. This comparison breaks down Ambrosia's 14 real-time engines and 1,500+ curated deals against PitchBook's VC/PE-centric platform to help you pick the right tool for licensing, partnering, and valuation work.
Eli Lilly is paying $2.3B to acquire Ajax Therapeutics and its small molecule oncology platform — a bold move for an asset with no disclosed phase. Here's what the deal structure tells us about Lilly's conviction and what it means for comparable oncology assets.
Fourteen real-time benchmarking engines versus a clinical-trial-centric intelligence suite — the Cortellis alternative debate comes down to what BD teams actually need at the negotiation table. Here's the data-driven breakdown.
Antibody licensing 2026 exploded from zero deals in H2 2025 to 28 in H1 2026 — a 2800% increase. With Pfizer, AbbVie, and GSK all making aggressive moves, the modality is commanding historic premiums. Here's what the data says and what it means for your next term sheet.
Roche closed 53 deals between mid-2023 and mid-2026, with a sharp concentration in oncology and a late-period pivot into gastroenterology and platform acquisitions. Their 38.3% average upfront ratio and heavy use of collaborations reveal a buyer that wants optionality — and knows how to get it.
Mega deal activity exploded by 4300% in the first half of 2026, jumping from zero transactions to 43 in six months. The data points to a structural shift in how Big Pharma is addressing pipeline gaps — and the implications for deal teams are immediate.
Roche's $1.5B acquisition of PathAI marks the largest digital pathology deal in biopharma history. We break down the PathAI Roche Holding AG deal structure, competitive context, and what it signals for AI-enabled diagnostics valuations.
The median upfront for an approved small molecule dermatology deal is $612M, based on 5 benchmarked transactions with a P25–P75 range of $540M–$1.2B. Here's what drives the spread and how to position your asset at the top of the range.
BD teams evaluating a GlobalData alternative for deal benchmarking face a core tradeoff: pipeline breadth vs. deal-term depth. This comparison breaks down 14 Ambrosia engines against GlobalData's platform across pricing, data granularity, and real-world BD utility.
Deals classified outside traditional therapeutic silos jumped 4900% in the first half of 2026, from 1 transaction to 50. Platform technology plays, tools-based licensing, and cross-domain collaborations are reshaping how pharma BD teams source assets.
Fourteen benchmarking engines and 1,530 unique data points versus consensus revenue forecasts — the gap between Ambrosia and Evaluate Pharma matters when you're structuring a $500M licensing deal. This comparison breaks down exactly where each tool wins and where it falls short for biopharma BD professionals.
Novartis closed 56 deals between March 2024 and July 2026, with a heavy concentration in oncology and ADC platform acquisitions. The average upfront ratio sits at 21.8% of TDV — buyer-friendly territory that signals a pharma playing the long game with milestone-heavy structures.
Novartis paid $1.5B to acquire Myricx Bio's ADC payload platform at discovery stage — one of the largest preclinical ADC acquisitions on record. Here's what the Myricx Bio Novartis deal structure tells us about where payload technology valuations are headed.
The median upfront for a preclinical bispecific antibody oncology deal is $55M across 58 analyzed transactions, with a P25–P75 range of $37M–$95M. Here's what drives the spread and how to position your asset at the top of it.
The median upfront for an approved small molecule oncology deal is $2,400M across 23 analyzed transactions, with a P25–P75 range spanning $588M to $11,500M. Here's what drives that 20x spread and where your asset likely falls.
AstraZeneca paid $200M upfront to license TQC3721, a dual PDE3/PDE4 inhibitor, from Sino Biopharmaceutical in a deal valued at $1.9B. The 10.5% upfront-to-TDV ratio signals measured conviction with heavy milestone loading — here's what the structure reveals about AstraZeneca's respiratory strategy and what it means for comparable assets.
Bristol Myers Squibb and Hengrui Pharmaceuticals announced a $15.2B broad drug collaboration — the largest China-originated pharma partnership in history. Here's what the deal structure tells us about BMS's post-Revlimid strategy and what it means for comparable asset valuations.
Fourteen real-time benchmarking engines versus a legacy deal database — which platform actually gives BD teams the granularity they need to negotiate? We compared Ambrosia and DealForma across data depth, valuation capabilities, and pricing so you don't have to.
The median upfront for a preclinical gene therapy rare disease deal is $185M across 12 transactions, but the P25–P75 spread runs from $42M to $1,025M. That 24x gap tells you more about deal dynamics than any single headline number. Here's what drives it and where your asset likely falls.
AbbVie executed 59 deals between late 2023 and mid-2026, committing over $30B in total deal value across co-development, licensing, and acquisitions. The pattern is unmistakable: AbbVie is rebuilding its immunology moat while quietly assembling a next-generation oncology pipeline.
The median upfront payment for a Phase 2 monoclonal antibody neurology acquisition now sits at $284M — but the five largest recent deals in this space all closed with $0 upfront. That paradox tells you everything about how neurology M&A actually works, and why standard benchmarks mislead both buyers and sellers.
The median upfront payment for a Phase 2 small molecule oncology acquisition just hit $284M — and the total deal values are pushing past $3.9B. We break down exactly what's driving these numbers, deconstruct the biggest comparable deals of 2025, and provide the negotiation playbook your deal team actually needs.
The median upfront for an ASO women's health acquisition at Phase 2 is $284M — but the spread between floor and ceiling is over $600M. This analysis breaks down why, deconstructs the five most relevant comparable deals, and gives BD teams and founders the frameworks they need to negotiate from data, not intuition.
Novartis just dropped $1.1B to acquire Myricx, adding another ADC asset to its oncology arsenal. The deal clears our Phase 2 oncology acquisition benchmarks on total value but raises questions about upfront structure. Here's what the numbers actually say — and what dealmakers should take away before their next term sheet.
The median upfront for a Phase 2 radiopharmaceutical gastroenterology acquisition now sits at $275M — but total deal values stretch past $3.3B when milestone stacks are fully loaded. Here's how the biggest GI radiopharmaceutical deals are actually structured, what the benchmark data reveals, and what you should demand at the table.
The median upfront for a Phase 2 peptide dermatology acquisition now sits at $275M, but total deal values stretch beyond $3.3B — a spread that reveals how acquirers are pricing clinical and commercial risk in one of pharma's most competitive therapeutic areas. Here's how the deal structures actually break down and what they mean for your next negotiation.
The median upfront for a Phase 2 CAR-T ophthalmology acquisition just crossed $120M — yet total deal values are stretching to $2.5B, revealing a massive conviction gap between what acquirers will pay now versus what they think these assets are worth. Here's how the deal math actually works, what recent ophthalmology acquisitions tell us about buyer psychology, and why the conventional playbook is wrong.
The median upfront for a Phase 2 PROTAC infectious disease acquisition is $275M — but total deal values stretch past $3.3B when milestones are stacked right. We break down exactly how these deals are structured, what the comparables tell you, and where the negotiation leverage actually sits.
The median upfront for a Phase 2 mRNA hematology acquisition now sits at $275M — but total deal values are stretching past $3B. We break down the benchmark data, deconstruct the biggest comparable deals, and deliver a negotiation playbook for both founders and BD professionals.
The median upfront for an RNAi rare disease acquisition at Phase 2 is $275M — but the spread between the floor and ceiling reveals a market that prices platform potential very differently from single-asset value. Here's what the benchmark data, comparable transactions, and deal structures actually tell sophisticated negotiators heading into 2025-2026 term sheets.
The median upfront for a Phase 2 cell therapy cardiovascular acquisition now sits at $275M — but total deal values routinely blow past $3B. We break down comparable deals, introduce the Regenerative Risk Premium framework, and give both founders and BD teams a negotiation playbook grounded in 2024-2025 transaction data.
The median upfront for a Phase 2 gene therapy metabolic acquisition now sits at $120M — but total deal values stretch to $2.5B, meaning acquirers are structuring 80%+ of consideration as contingent milestones. We break down what these structures actually mean for sellers and buyers.
The median upfront for a Phase 2 monoclonal antibody immunology acquisition now sits at $275M — but total deal values stretch past $3.3B. We break down the benchmark data, deconstruct the 2025 comps rewriting the playbook, and show you exactly where the leverage sits for both buyers and sellers.
The median upfront payment for a small molecule neurology acquisition at Phase 2 is $120M — but the real story is in the total deal values now routinely exceeding $1B. We break down five comparable transactions, introduce the Neuro Premium Multiplier framework, and deliver a negotiation playbook for both founders and BD teams.
The median upfront for a Phase 2 bispecific antibody oncology acquisition has hit $275M — and total deal values are routinely breaching $3B. We break down the five biggest comparable deals, introduce a framework for evaluating buyer conviction, and deliver a negotiation playbook for both founders and BD teams.
The median upfront for a Phase 2 radiopharmaceutical women's health acquisition now sits at $275M — but total deal values stretch beyond $3.3B, revealing a massive conviction gap between what buyers pay at signing and what they promise on the back end. Here's what the benchmark data, comparable transactions, and deal structures actually tell us about where this niche is heading.
The median upfront for a Phase 2 peptide gastroenterology acquisition is $120M, but total deal values are stretching past $2.5B as Big Pharma chases GI pipeline gaps. Here's exactly how these deals are structured, why the milestone-to-upfront ratios reveal buyer conviction, and what BD teams should demand at the table.
The median upfront for a Phase 2 CAR-T (hematologic) dermatology acquisition now sits at $275M — but total deal values stretch beyond $3.3B when milestones play out. We break down every lever, deconstruct the biggest comparable transactions, and hand you a negotiation playbook built for the current market.
The median upfront for a Phase 2 PROTAC ophthalmology acquisition now sits at $120M — but the spread between the floor and ceiling tells a far more important story. We break down the benchmarks, deconstruct the biggest comparable deals, and deliver a tactical playbook for founders and BD teams negotiating in this emerging sweet spot.
The median upfront for an mRNA infectious disease acquisition at Phase 2 is $275M — but total deal values routinely exceed $1B. We break down the benchmarks, deconstruct the biggest comps, and offer a tactical playbook for both sides of the table.
The median upfront for an RNAi hematology acquisition at Phase 2 is $275M — but total deal values are stretching past $3B. We break down the benchmark data, deconstruct the biggest recent deals, and lay out a negotiation playbook for both sides of the table.
The median upfront for a Phase 2 cell therapy rare disease acquisition now sits at $342.5M — a figure that would have been unthinkable five years ago. We break down the benchmark data, deconstruct the deals that set these precedents, and lay out what BD teams and founders should demand at the table.
The median upfront payment for a Phase 2 gene therapy cardiovascular acquisition now sits at $342.5M — a number that would have been unthinkable five years ago. We break down the benchmark data, deconstruct the biggest recent deals, and deliver a negotiation playbook for both biotech founders and pharma BD professionals.
The median upfront for a Phase 2 monoclonal antibody metabolic acquisition now sits at $342.5M — a number that would have been unthinkable outside oncology five years ago. Here's what's driving the premiums, how the biggest deals were structured, and what your term sheet should look like.
The median upfront for a Phase 2 small molecule immunology acquisition just hit $342.5M — and the total deal value ceiling has blown past $3.5B. We break down the benchmark data, deconstruct the five deals defining this market, and lay out what BD teams and founders need to negotiate from a position of strength.
The median upfront for a Phase 2 bispecific antibody neurology acquisition now sits at $342.5M — a number that would have been unthinkable five years ago. We break down the deal terms, deconstruct the comparable transactions, and give you a negotiation playbook backed by verified benchmarks.
The median upfront for a peptide women's health licensing deal at Phase 2 has hit $342.5M — a number that would have been unthinkable three years ago. Here's why the economics shifted, what the comparable deals actually tell us, and how to negotiate from either side of the table.
The median upfront for a Phase 2 CAR-T (hematologic) gastroenterology licensing deal has hit $342.5M — a number that would have been unthinkable three years ago. Here's what's driving the inflation, how the biggest deals were structured, and what it means for your next term sheet.
The median upfront for a Phase 2 PROTAC dermatology licensing deal now sits at $120M, with total deal values stretching to $2.5B. We break down the benchmark data, deconstruct the biggest comparable deals, and offer a tactical negotiation playbook for founders and BD teams navigating this white-hot modality.
The median upfront for a Phase 2 mRNA ophthalmology licensing deal has hit $342.5M — a number that would have been unthinkable three years ago. Here's the benchmark data, the deal structures behind it, and what it means for your next term sheet.
The median upfront payment for a Phase 2 RNAi infectious disease licensing deal now sits at $342.5M — a figure that would have been inconceivable five years ago. We break down the benchmark data, deconstruct the comparable deals, and provide a tactical negotiation playbook for both founders and BD professionals.
The median upfront for a Phase 2 cell therapy hematology licensing deal has hit $120M, with total deal values stretching to $2.5B. We break down the benchmark data, deconstruct the biggest comparable transactions, and deliver a tactical negotiation playbook for both biotech founders and pharma BD teams.
The median upfront for a Phase 2 gene therapy rare disease licensing deal now sits at $342.5M — a number that would have been unthinkable five years ago. Here's what's driving those economics, how the biggest recent deals were structured, and what BD teams and founders need to know before they sit down at the table.
The median upfront payment for a Phase 2 monoclonal antibody cardiovascular licensing deal now sits at $342.5M — a number that would have been unthinkable three years ago. We break down the benchmark data, deconstruct five real comparable deals, and deliver the negotiation playbook BD teams and founders actually need.
The median upfront payment for a small molecule metabolic licensing deal at phase 2 is now $120M — but the real story is in the zero-upfront mega-deals reshaping the market. We break down the benchmarks, deconstruct the biggest 2024–2025 comps, and give you the negotiation playbook.
The median upfront for a Phase 2 bispecific antibody immunology licensing deal has hit $340M — a number that would have been laughable five years ago. Here's what's driving the inflation, how the biggest 2025 deals were structured, and what your next term sheet should look like.
The median upfront for a Phase 2 ADC neurology licensing deal now sits at $120M, with total deal values stretching to $2.5B. We break down the benchmark data, deconstruct the biggest recent neurology deals, and deliver a tactical negotiation playbook for both founders and BD professionals.
The median upfront for an anti-VEGF oncology licensing deal at Phase 2 has hit $340M — a number that would have been a total deal value five years ago. We break down the benchmark data, deconstruct the five largest comparable deals, and give you the negotiation playbook your deal committee actually needs.
The median upfront for a Phase 2 CAR-T (hematologic) women's health licensing deal now sits at $120M — a number that would have been unthinkable three years ago. We break down the benchmark data, deconstruct comparable deals, and deliver the negotiation playbook BD teams actually need.
The median upfront for a Phase 2 PROTAC gastroenterology licensing deal has hit $340M — a number that would have been unthinkable three years ago. Here's what's driving the premiums, how the biggest deals were structured, and what BD teams need to know before the next term sheet lands.
The median upfront for an mRNA dermatology licensing deal at Phase 2 is now $340M — a number that would have been unthinkable three years ago. Here's the full benchmark breakdown, comparable deal analysis, and a negotiation playbook built for the people actually sitting across the table.
The median upfront for a Phase 2 RNAi ophthalmology licensing deal has hit $340M — a number that would have been unthinkable three years ago. We break down the benchmark data, deconstruct the biggest comparable deals, and give you the negotiation playbook for both sides of the table.
The median upfront for a Phase 2 cell therapy infectious disease licensing deal has hit $340M — a number that would have been absurd five years ago. Here's the full benchmark breakdown, deal deconstructions, and a negotiation playbook for both founders and BD professionals.
The median upfront for a Phase 2 gene therapy hematology licensing deal is now $340M — a number that would have been unthinkable three years ago. We break down the benchmark data, deconstruct the biggest comparable deals, and deliver a tactical negotiation playbook for both founders and BD teams.
The median upfront payment for a Phase 2 monoclonal antibody rare disease licensing deal now sits at $340M — a number that would have been unthinkable five years ago. Here's what's driving the inflation, how the smartest deal teams are structuring terms, and where the market is heading in 2025–2026.
The median upfront for a Phase 2 small molecule cardiovascular licensing deal now sits at $340M — a figure that would have been unthinkable five years ago. We break down the benchmark data, deconstruct five real deals, and deliver the negotiation playbook BD teams and founders actually need.
GSK is acquiring Nuvalent, the ROS1/ALK-focused lung cancer biotech, for $10.6 billion — a deal that blows past every standard Phase 2 oncology acquisition benchmark by an order of magnitude. Here's what the premium signals about where Big Pharma is placing its bets on small molecule targeted oncology in 2026.
The median upfront for a Phase 2 bispecific antibody metabolic licensing deal has hit $340M — a number that would have been inconceivable three years ago. We break down the benchmark data, deconstruct the biggest comparable deals, and deliver the negotiation playbook BD teams actually need.
The median upfront payment for a Phase 2 ADC immunology licensing deal has hit $340M — a number that would have been considered fantasy three years ago. We break down the benchmark data, deconstruct five real 2025 comparable deals, and deliver a tactical negotiation playbook for both biotech founders and pharma BD teams.
Roche has committed up to $700M to license Nurix Therapeutics' BTK protein degrader bexobrutideg, marking one of the more significant small molecule oncology collaboration deals of 2026. The upfront terms signal that Big Pharma is willing to pay a meaningful premium for differentiated degrader assets. Here's how the deal stacks up against benchmark data and what it means for BD teams working similar assets.
Roche has committed up to $700M to Nurix Therapeutics for rights to bexobrutideg, a BTK-targeting protein degrader in Phase 2. The deal lands at the floor of Phase 2 oncology total value benchmarks — but the modality premium and strategic timing tell a more complicated story.
The median upfront for an anti-VEGF neurology licensing deal at Phase 2 has reached $316M — a figure that would have been unthinkable three years ago. Here's what's driving valuations, how the biggest recent neurology deals were structured, and what your term sheet should look like.
The median upfront for a Phase 2 GLP-1 agonist oncology licensing deal now sits at $316M — a figure that would have been considered a Phase 3 premium just two years ago. Here's the full benchmark breakdown, deal deconstructions, and a negotiation playbook built for the current market.
The median upfront for a Phase 2 PROTAC women's health licensing deal now sits at $316M — a number that would have been unthinkable three years ago. We deconstruct the benchmark data, break down real comparable deals, and lay out the negotiation playbook for both founders and BD teams.
Eli Lilly just bet $1.9 billion on RNA exon editing through a new pact with Ascidian Therapeutics targeting kidney disease. The deal is a landmark for an emerging modality — and a data point every BD team should be watching. Here's the full breakdown.
The median upfront for a Phase 2 mRNA gastroenterology licensing deal has hit $316M — a number that would have been unthinkable three years ago. Here's how the deal structures actually break down, what the comparable transactions reveal about buyer conviction, and where the negotiation leverage really sits.
The median upfront for an RNAi dermatology licensing deal at Phase 2 has hit $316M — a number that would have been absurd five years ago. Here's what's driving the premium, how the biggest deals were structured, and what your next term sheet should look like.
Regeneron paid Telix $40M to enter radiopharma — 1% of what BMS paid for RayzeBio. A structural breakdown of why the deal signals the end of radiopharma's M&A era, and what comes next for the eight big pharmas still without a radiopharma presence.
Gilead's $465M option/license deal with Tubulis signals a disciplined re-entry into the ADC space after Trodelvy setbacks. We break down the deal economics, rNPV framework, and what the structure reveals about large pharma ADC strategy in 2026.
Over $40B in biopharma partnership value was terminated in 2024 alone. We analyze the top terminations, the pattern of serial deal dissolutions, and how this trend is reshaping out-licensing strategy and deal structure negotiations.
Neurocrine's $2.9B all-cash acquisition of Soleno Therapeutics adds VYKAT XR — the first approved treatment for Prader-Willi Syndrome hyperphagia — to a growing rare disease portfolio. We model the deal economics, assess the acquisition premium, and benchmark against rare disease M&A history.
Oncology remains the dominant therapeutic area for biopharma M&A, with ADCs driving the largest transactions. This comprehensive benchmarking report analyzes deal structures across clinical stages, models returns under uncertainty, and identifies which pharma companies still need ADC franchises.
Drawing from thousands of disclosed biopharma deals, we distill seven negotiation strategies that consistently produce better licensing terms for biotech companies.
Phase 2 biotech assets consistently command 2-4x the deal values of Phase 1 programs. We explain the mechanics behind the phase transition premium and how to use it in negotiations.
The obesity drug market has transformed biopharma deal-making. From dual incretins to oral GLP-1 formulations, we analyze how the metabolic deal landscape is evolving in 2026.
ADC licensing deals have reached unprecedented valuations in 2026. We break down the forces behind this surge and what it means for deal teams negotiating their next partnership.
Get data-driven deal terms for any therapeutic area, modality, and clinical phase. Powered by 1,600++ verified biopharma transactions.
Try Solidus